Ascendis Pharma initiates long-term study of Skytrofa
A new study is expected to go on for ten years, and will investigate the potential long-term safety risks of the growth hormone deficiency treatment.
by christopher due karlsson, translated by daniel pedersen
This month, Danish biotech company Ascendis Pharma initiated a long-term study of Skytrofa (lonapegsomatropin), which is a treatment for growth hormone deficiency.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ascendis Pharma books EUR 583m loss in 2022
For subscribers
